NIKKEI 225
27,772.93 +305.70 (+1.11%) HANG SENG
24,952.35 +824.50 (+3.42%) CRUDE OIL
86.91 -0.05 (-0.06%) GOLD FUTURES
1,847.80 +4.60 (+0.25%) DOW
34,715.39 -313.26 (-0.89%) BTC-GBP
31,128.51 +253.11 (+0.82%)
Guardant Health, Inc. (GH)
After hours:
| Previous close | 72.00 |
| Open | 73.36 |
| Bid | 75.83 x 1100 |
| Ask | 76.05 x 1000 |
| Day's range | 72.32 - 77.14 |
| 52-week range | 71.11 - 181.07 |
| Volume | |
| Avg. volume | 1,103,808 |
| Market cap | 7.395B |
| Beta (5Y monthly) | 0.45 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium
REDWOOD CITY, Calif., January 19, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data highlighting the clinical utility of its liquid biopsy tests in the treatment and management of early- to late-stage gastrointestinal cancers, including colorectal cancer, at the 2022 ASCO Gastrointestinal Cancers Symposium being held January 20-22, 2022.
- Business Wire
Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults
REDWOOD CITY, Calif., January 18, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the enrollment of the first patient in the SHIELD (Screening for HIgh-frEquency maLignant Disease) LUNG study, a nearly 10,000-patient prospective, registrational study to evaluate the performance of its next-generation Guardant SHIELD blood test in detecting lung cancer in high-risk individuals ages 50-80. The study is anticipated to run in approximately 100 centers
- Business Wire
Guardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology Litigation
REDWOOD CITY, Calif., January 07, 2022--Guardant Health, Inc. (Nasdaq: GH) today announced that it has reached an agreement to settle all pending litigation concerning the company’s digital sequencing technology patents with Foundation Medicine, Inc. Pursuant to the settlement agreement, Foundation Medicine will pay Guardant Health $25 million as well as future royalties for the remaining term of the licensed digital sequencing technology patents. In turn, Guardant Health will grant Foundation M
